.Attribute Medicine, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of individuals along with HER2+ enhanced bosom cancer cells as well as active or secure brain metastases revealed consistent intracranial activity and also wide spread efficiency of T-DXd.